SEC Filings

Form 10-Q
DURECT CORP filed this Form 10-Q on 05/07/2019
Document Outline
Entire Document (3973.1 KB)
Subdocument 1 - 10-Q - 10-Q
Page 1 - UNITED STATES
Page 2 - N/A
Page 3 - INDEX
Page 4 - PART I. FINANCIAL INFORMATION
Page 5 - DURECT CORPORATION
Page 6 - DURECT CORPORATION
Page 7 - DURECT CORPORATION
Page 8 - DURECT CORPORATION
Page 9 - Leases
Page 10 - Collaborative Research and Development Revenues
Page 11 - Comprehensive Loss
Page 12 - Recently Issued Accounting Standards
Page 13 - Note 2. Strategic Agreements
Page 14 - Agreement with Sandoz AG
Page 15 - N/A
Page 16 - Note 4. Stock-Based Compensation
Page 17 - Note 6. Commitments
Page 18 - Note 7. Stockholders Equity
Page 19 - Forward-looking statements made in this report include, for example, statements about:
Page 20 - Forward-looking statements are not guarantees of future performance and involve risks and uncertaint
Page 21 - Acute Organ Injury Program with Injectable DUR-928
Page 22 - Clinical Program
Page 23 - Methurin P. et al. Gut 2011; 60:255-260
Page 24 - MELD is calculated based on (a) bilirubin, (b) serum creatinine (sCr), and (c) International Normali
Page 25 - Clinical program.
Page 26 - Additional Proprietary Pharmaceutical Programs
Page 27 - Status.
Page 28 - Efficacy
Page 29 - Plans for FDA Submission
Page 30 - REMOXY ER
Page 31 - The ORADUR Sustained Release Gel Cap Technology
Page 32 - Critical Accounting Policies and Estimates
Page 33 - Research and development
Page 34 - ORADUR-ADHD
Page 35 - N/A
Page 36 - Off-Balance Sheet Arrangements
Page 37 - PART II OTHER INFORMATION
Page 38 - The path to regulatory approval of DUR-928 is uncertain
Page 39 - The FDA may require more information or clinical studies for all of our product candidates, and our
Page 40 - We will require and may have difficulty raising needed capital in the future
Page 41 - We do not control the commercialization of PERSERIS or Methydur
Page 42 - Cancellation of collaborations regarding our product candidates may adversely affect potential econo
Page 43 - Our revenues also depend on milestone payments based on achievements by our third-party collaborator
Page 44 - Failure to comply with ongoing governmental regulations for our pharmaceutical product candidates co
Page 45 - We may develop our own sales force and commercial group to market future products but we have limite
Page 46 - Some of our pharmaceutical product candidates contain controlled substances, the making, use, sale,
Page 47 - Global credit and financial market conditions could negatively impact the value of our current portf
Page 48 - Cyber-attacks or other failures in telecommunications or information technology systems could result
Page 49 - Our collaboration agreements may depend on our intellectual property
Page 50 - Risks Related To Our Industry
Page 51 - Our relationships with customers and third-party payers will be subject to applicable anti-kickback,
Page 52 - Healthcare reform measures could hinder or prevent our product candidates commercial success.
Page 53 - We could be exposed to significant product liability claims which could be time consuming and costly
Page 54 - If users of our products are unable to obtain adequate reimbursement from third-party payers, or if
Page 55 - Risks Related To Our Common Stock
Page 56 - Our ability to use net operating losses and certain other tax attributes is uncertain and may be lim
Page 57 - We have broad discretion over the use of our cash and investments, and their investment may not alwa
Page 58 - Our bylaws provide that the Court of Chancery of the State of Delaware is the exclusive forum for su
Page 59 - N/A
Page 60 - SIGNATURES
Subdocument 2 - EX-31.1 - EX-31.1
Page 1 - N/A
Subdocument 3 - EX-31.2 - EX-31.2
Page 1 - N/A
Subdocument 4 - EX-32.1 - EX-32.1
Page 1 - N/A
Subdocument 5 - EX-32.2 - EX-32.2
Page 1 - N/A
XBRL Item - EX-101.INS - XBRL INSTANCE DOCUMENT (What's this?)
XBRL Item - EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA (What's this?)
XBRL Item - EX-101.CAL - XBRL TAXONOMY EXTENSION CALCULATION LINKBASE (What's this?)
XBRL Item - EX-101.DEF - XBRL TAXONOMY EXTENSION DEFINITION LINKBASE (What's this?)
XBRL Item - EX-101.LAB - XBRL TAXONOMY EXTENSION LABEL LINKBASE (What's this?)
XBRL Item - EX-101.PRE - XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE (What's this?)
XBRL Viewer